Matches in SemOpenAlex for { <https://semopenalex.org/work/W2965629056> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W2965629056 endingPage "51" @default.
- W2965629056 startingPage "47" @default.
- W2965629056 abstract "Regorafenib is an oral multikinase inhibitor; the CORRECTtrial evaluated its efficacy in patients with metastatic colorectal cancer following disease progression with standard therapies. However, regorafenib has toxicities that develop quickly. Few studies have reported the safe dose and usage of regorafenib to avoid these adverse events in Japanese patients. We examined the side effects and safe administration technique of regorafenib in this study. We administered regorafenib to 15 patients with metastatic colorectal cancer following disease progression with standard therapies. Between August 2013 and January 2014, 5 patients received 160 mg oral regorafenib once daily on days 1-21 of a 28 day course(group A). Between February 2014 and July 2015, 10 patients received initiating therapy with 120 mg regorafenib, with the intention of increasing the dose(group B). We retrospectively assessed side effects, number of dose courses, and total dose of regorafenib in both groups. The median dosing course was 5 coureses in group B, which was more than the 1 course in group A. The median total dose was 10,800 mg in group B, which is about 4 times as much as the 2,400 mg in group A. In group B, 7 out of 10 patients (70%)were successful in the dose escalation of regorafenib from 120 to 160 mg daily over 3-5 courses. The disease control rate was 40% in both groups. The rate of adverse events of Grade 3 or higher was 60% in group A, compared to 40% in group B within 2 courses. The overall survival time was 308 days in group B, which was significantly longer than the 168 days in group A. Initiating therapy with 120 mg regorafenib with the intention of increasing the dose improves safety and allows an increase in dosing courses, as well as in the total dose of regorafenib and overall survival time." @default.
- W2965629056 created "2019-08-13" @default.
- W2965629056 creator A5010629935 @default.
- W2965629056 creator A5053784930 @default.
- W2965629056 creator A5060716896 @default.
- W2965629056 creator A5061109504 @default.
- W2965629056 creator A5062468905 @default.
- W2965629056 creator A5075231755 @default.
- W2965629056 creator A5076947828 @default.
- W2965629056 creator A5080103837 @default.
- W2965629056 creator A5081243390 @default.
- W2965629056 creator A5083613461 @default.
- W2965629056 creator A5084629531 @default.
- W2965629056 date "2017-01-01" @default.
- W2965629056 modified "2023-09-27" @default.
- W2965629056 title "[Investigation of Administration Technique of Regorafenib in Our Center]." @default.
- W2965629056 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28174379" @default.
- W2965629056 hasPublicationYear "2017" @default.
- W2965629056 type Work @default.
- W2965629056 sameAs 2965629056 @default.
- W2965629056 citedByCount "0" @default.
- W2965629056 crossrefType "journal-article" @default.
- W2965629056 hasAuthorship W2965629056A5010629935 @default.
- W2965629056 hasAuthorship W2965629056A5053784930 @default.
- W2965629056 hasAuthorship W2965629056A5060716896 @default.
- W2965629056 hasAuthorship W2965629056A5061109504 @default.
- W2965629056 hasAuthorship W2965629056A5062468905 @default.
- W2965629056 hasAuthorship W2965629056A5075231755 @default.
- W2965629056 hasAuthorship W2965629056A5076947828 @default.
- W2965629056 hasAuthorship W2965629056A5080103837 @default.
- W2965629056 hasAuthorship W2965629056A5081243390 @default.
- W2965629056 hasAuthorship W2965629056A5083613461 @default.
- W2965629056 hasAuthorship W2965629056A5084629531 @default.
- W2965629056 hasConcept C121608353 @default.
- W2965629056 hasConcept C126322002 @default.
- W2965629056 hasConcept C141071460 @default.
- W2965629056 hasConcept C197934379 @default.
- W2965629056 hasConcept C2776248978 @default.
- W2965629056 hasConcept C2777288759 @default.
- W2965629056 hasConcept C526805850 @default.
- W2965629056 hasConcept C71924100 @default.
- W2965629056 hasConceptScore W2965629056C121608353 @default.
- W2965629056 hasConceptScore W2965629056C126322002 @default.
- W2965629056 hasConceptScore W2965629056C141071460 @default.
- W2965629056 hasConceptScore W2965629056C197934379 @default.
- W2965629056 hasConceptScore W2965629056C2776248978 @default.
- W2965629056 hasConceptScore W2965629056C2777288759 @default.
- W2965629056 hasConceptScore W2965629056C526805850 @default.
- W2965629056 hasConceptScore W2965629056C71924100 @default.
- W2965629056 hasIssue "1" @default.
- W2965629056 hasLocation W29656290561 @default.
- W2965629056 hasOpenAccess W2965629056 @default.
- W2965629056 hasPrimaryLocation W29656290561 @default.
- W2965629056 hasRelatedWork W2003938723 @default.
- W2965629056 hasRelatedWork W206168401 @default.
- W2965629056 hasRelatedWork W2095162893 @default.
- W2965629056 hasRelatedWork W2118496982 @default.
- W2965629056 hasRelatedWork W2378448584 @default.
- W2965629056 hasRelatedWork W2418367671 @default.
- W2965629056 hasRelatedWork W2439875401 @default.
- W2965629056 hasRelatedWork W2469234617 @default.
- W2965629056 hasRelatedWork W2746129386 @default.
- W2965629056 hasRelatedWork W2525756941 @default.
- W2965629056 hasVolume "44" @default.
- W2965629056 isParatext "false" @default.
- W2965629056 isRetracted "false" @default.
- W2965629056 magId "2965629056" @default.
- W2965629056 workType "article" @default.